OTC : CSLLY

CSL Limited

$23.74 USD

$0.23 (0.96%)

Volume
5.88K
Average Volume
436.7K
Market Capitalization
$91.93B
P/E Ratio
31.88
Dividend Yield
3.17%
Price Target
$153.50
Year High
$44.78
Year Low
$16.01
Day High
—
Day Low
—
Payout Ratio
$1.03
Current Ratio
$2.57
Company Overview

OTC

Gordon Naylor DipCompSc

Biotechnology

Healthcare

CSLLY

29000

AU

USD

https://www.csl.com

61 3 9389 1911

12637N204

0001274152

Liquidity Metrics

0.67

2.57

1.15

0.25

1.03

Sales & Valuation

$15.43B

2.90

2.46

14.31

3.29

Profitability

$0.39

$3B

9.17%

10.29%

7.56%

3.80%

P/E Metrics

31.88

-0.59

-0.59

Analyst Price Target & Rating

$153.50

$153.50

$153.50

Neutral

3/5

0 Analysts

-84.53%

Financial Health Scores

5.48

6/9

$7.24B

$37.9B

$17.44B

$8.08B

Key Metrics (TTM)

$56.94B

3.63

11.07

2.57

7.56%

10.37%

3.13%

6.99%

$50.86

250 days

Company Executives
Name Title
William Mezzanotte Chief Medical Officer, Executive Vice President and Head of Research & Development
Gordon Naylor DipCompSc CEO, MD & Director
Gregory Boss Executive VP of Legal & Group General Counsel
Amy Van Buren Chief People Officer
Mary Oates Executive VP & COO
Ken Lim Chief Financial Officer
Mark Dehring Head of Investor Relations
Mark Hill Chief Digital Information Officer & Executive Vice President
Stephen Marlow Executive VP & GM of CSL Plasma
Deirdre BeVard Senior Vice President of Research & Development Strategic Operations
Poll Results

No votes yet today — be the first to share your view!

About CSL Limited (OTC:CSLLY) Stock

CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments ... . This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.

CSL Q2 Earnings Beat Estimates on Record Sales, Outlook Raised

2026-07-30 12:41:12

Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.

CSL to start clinical trials for new immunoglobulin manufacturing process

2026-07-28 21:00:18

Australian biotechnology firm CSL said on Wednesday it would start clinical trials ​to support regulatory approval for a new ‌manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma.

CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)

2026-07-27 09:00:00

CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).

CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union

2026-06-26 09:00:00

Recommendation follows an Article 20 non-pharmacovigilance procedure  Patients currently on TAVNEOS treatment should consult their treating physician   ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan).

CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations

2026-06-12 12:35:00

SYDNEY, June 12, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, and Adbri announce the delivery of MV Yampu, the world's first battery-powered self-unloading bulk carrier. The vessel was officially delivered at Jiangjiang Nanyang Shipyard on June 5, 2026, and has now departed on its maiden voyage to commence operations for Adbri in Birkenhead, South Australia.

Australia says CSL unit Seqirus to discontinue Benpen injections from November

2026-05-27 03:20:38

Australia's drug regulator ​said on Wednesday ‌it was notified by ​biopharmaceutical ​giant CSL's unit Seqirus ⁠that ​it will be ​discontinuing all strengths of their ​Benpen injection ​products progressively due ‌to ⁠commercial reasons.

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

2026-05-14 15:30:47

CSL Limited (CSLLY) Shareholder/Analyst Call Transcript

Frequently Asked Questions

What is the current CSL Limited (CSLLY) stock price?

CSL Limited(OTC:CSLLY) stock price is $23.74 in the last trading session. During the trading session, CSLLY stock reached the peak price of $44.775 while $16.01 was the lowest point it dropped to. The percentage change in CSLLY stock occurred in the recent session was 0.96% while the dollar amount for the price change in CSLLY stock was $0.23.

CSLLY's industry and sector of operation?

The OTC listed CSLLY is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CSLLY?

William Mezzanotte | Chief Medical Officer, Executive Vice President and Head of Research & Development
Gordon Naylor DipCompSc | CEO, MD & Director
Gregory Boss | Executive VP of Legal & Group General Counsel
Amy Van Buren | Chief People Officer
Mary Oates | Executive VP & COO

How many employees does CSLLY have?

Number of CSLLY employees currently stands at 29000. CSLLY operates from 655 Elizabeth Street, Melbourne, VIC 3000, AU.

Link for CSLLY official website?

Official Website of CSLLY is: https://www.csl.com

How do I contact CSLLY?

CSLLY could be contacted at phone #61 3 9389 1911 and can also be accessed through its website. CSLLY operates from 655 Elizabeth Street, Melbourne, VIC 3000, AU.

How many shares of CSLLY are traded daily?

The average number of CSLLY shares traded daily for last 3 months was 436.7K.

What is the market cap of CSLLY currently?

The market value of CSLLY currently stands at $91.93B with its latest stock price at $23.74